Hikma Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hikma Pharmaceuticals plc
Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues
Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.
Trio Of Hikma Launches Includes New Icosapent Strength
Hikma has launched three new generics in quick succession, including a new strength of its icosapent ethyl capsules that rival Vascepa, as well as unique presentations of its cefazolin and labetalol injectables.
Hikma Expands In Canada With Four New Injectables
Hikma has bolstered its generic sterile injectables business in Canada with four new launches.
Hikma Manages To Stay Flat In 2022 Despite Generics Pressures
As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Custopharm, Inc.
- EIMC United Pharmaceuticals
- Roxane Laboratories, Inc.
- West-Ward Pharmaceuticals Corp.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.